Drug intelligence / Profile preview

BPF-001

Development stage: Unknown
Lead developer: Videregen
Modality: Device-based Delivery → Drug Delivery Systems, Cell Therapies

Overview

BPF-001 is a novel tissue-engineered airway product developed by Videregen Limited. It consists of expanded autologous bone marrow-derived mesenchymal stromal cells (MSCs) seeded onto a decellularized allogeneic patch of an airway scaffold. It is being investigated for the treatment of clinically significant bronchopleural fistula. Mesenchymal Stromal Cells (MSCs) are known to stimulate healing, reduce inflammation, and promote tissue regeneration.

Beyond the preview

Go deeper on BPF-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BPF-001.

Explore the full profile